CTXR חוב כולל להון Citius Pharma

The price action of Citius Pharmaceuticals (CTXR) securities reflects a total debt-to-equity ratio of 0.10. Citius Pharmaceuticals is focusing on establishing US distribution networks to independently bring drugs to market. While the business is independent of economic cycles, it remains sensitive to the cost of borrowing. High authority among critical care physicians confirms the effectiveness of their therapeutic approaches to severe hospital conditions.

This ratio is indispensable for stress-testing debt loads and assessing the financial stability of a portfolio asset. It measures the proportion of borrowed funds relative to equity, while the debt-to-equity chart for Citius Pharmaceuticals (CTXR) reflects the balance between credit leverage and the stability of revenues from hospital supplies of medications for the treatment of catheter-related infections.